Tirzepatide · evidence
Tirzepatide evidence: what the SURMOUNT trials actually show
The randomized tirzepatide evidence, weight-loss figures, maintenance/withdrawal data, and the microdosing gap.
The strongest tirzepatide evidence is for the approved product at its labeled dose, chiefly the SURMOUNT trial program. In SURMOUNT-1, approved tirzepatide produced about 20.9% mean weight loss versus roughly 3.1% on placebo. None of these trials studied a compounded product or a deliberate microdose, so the evidence does not transfer to below-label dosing. Compounded tirzepatide is not FDA approved.
What the approved-product trials showed
Published mean weight loss, approved tirzepatide trials (%) — approved labeled doses only
In SURMOUNT-1, approved tirzepatide at its labeled dose produced roughly 20.9% mean weight loss over about 68–72 weeks, far above placebo. The SURMOUNT-4 withdrawal design tested what happens when treatment continues versus stops, and consistently showed that stopping leads to substantial weight regain — a central fact for anyone thinking about cost and duration.
Trial dataset
| Trial | Design | N | Result | Source | ID |
|---|---|---|---|---|---|
| SURMOUNT-1 | RCT, 72 weeks, placebo-controlled | 2,539 | Up to about -20.9% at 15 mg vs -3.1% placebo | N Engl J Med 2022 | NCT04184622 · PMID 35658024 · DOI |
| SURMOUNT-2 | RCT, 72 weeks | 938 | About -12.8% to -14.7% vs -3.2% placebo | Lancet 2023 | NCT04657003 · PMID 37385274 · DOI |
| SURMOUNT-4 | RCT withdrawal design | 670 | Continued treatment maintained loss; withdrawal led to regain | JAMA 2024 | NCT04660643 · PMID 38078870 · DOI |
Machine-readable: studies.json, studies.csv. All nine trials carry verified NCT, PMID, and DOI identifiers.
What the evidence shows
- Approved tirzepatide at labeled doses produces clinically meaningful weight loss in randomized trials.
- Stopping treatment is associated with weight regain in withdrawal-design trials.
What the evidence does not show
- That a compounded tirzepatide microdose reproduces these results — it was never studied.
- That less-frequent or below-label dosing maintains the trial outcomes.
- That a compounded oral/sublingual tirzepatide shares the approved product's evidence.
What remains unknown
There is no randomized evidence that a deliberate tirzepatide microdose delivers meaningful weight loss, that compounded tirzepatide matches the approved product's pharmacokinetics, or that any below-label maintenance strategy preserves the trial results. These are gaps, and this page marks them as gaps rather than filling them with extrapolation.
Frequently asked questions
Is there evidence tirzepatide microdosing works?
No direct randomized evidence. The robust data are for approved tirzepatide at studied doses; a deliberate microdose's weight-management benefit is unproven.
How much weight did people lose on tirzepatide in trials?
About 20.9% mean weight loss in SURMOUNT-1 at the approved dose, versus roughly 3.1% on placebo.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.